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Abstract
Background: Several active ingredients proposed as vaginal microbicides have been shown paradoxically to
increase susceptibility to infection in mouse genital herpes (HSV-2) vaginal susceptibility models and in clinical trials.
In addition, “inactive ingredients” (or excipients) used in topical products to formulate and deliver the active
ingredient might also cause epithelial toxicities that increase viral susceptibility. However, excipients have not
previously been tested in susceptibility models.
Methods: Excipients commonly used in topical products were formulated in a non-toxic vehicle (the “HEC
universal placebo”), or other formulations as specified. Twelve hours after exposure to the excipient or a control
treatment, mice were challenged with a vaginal dose of HSV-2, and three days later were assessed for infection by
vaginal lavage culture to assess susceptibility.
Results: The following excipients markedly increased susceptibility to HSV-2 after a single exposure: 5% glycerol
monolaurate (GML) formulated in K-Y® Warming Jelly, 5% GML as a colloidal suspension in phosphate buffered
saline, K-Y Warming Jelly alone, and both of its humectant/solvent ingredients (neat propylene glycol and neat
PEG-8). For excipients formulated in the HEC vehicle, 30% glycerin significantly increased susceptibility, and a trend
toward increased HSV-2 susceptibility was observed after 10% glycerin, and 0.1% disodium EDTA, but not after
0.0186% disodium EDTA. The following excipients did not increase susceptibility: 10% propylene glycol, 0.18%,
methylparaben plus 0.02% propylparaben, and 1% benzyl alcohol.
Conclusions: As reported with other surfactants, the surfactant/emulsifier GML markedly increased susceptibility to
HSV-2. Glycerin at 30% significantly increased susceptibility, and, undiluted propylene glycol and PEG-8 greatly
increased susceptibility.
Background
Topically administered microbicides are placed in the
vagina or rectum where they are intended to prevent
infections by blocking pathogens before or soon after
entry, advantageously reducing systemic exposures
inherent with oral dosing. However, topical application
places microbicide formulations at sites where they risk
altering epithelial barrier function. Indeed several micro-
bicide Phase III trials have reported strong trends
toward or significant increases in HIV infection in the
active microbicide arms [1-4].
The intact cervicovaginal epithelium provides a sub-
stantial barrier against HIV infection. The rate of het-
erosexual male to female HIV transmission reported in
a comprehensive review averaged about 1 in 1250 acts;
even during the highly infectious stage immediately after
HIV acquisition in the male partner the rate averaged
less than 1 in 100 acts [5]. In both the SIV macaque
and the FIV macaque models, 10,000 times more virus
was required for infection via vaginal challenge than via
parenteral challenge [6,7]. It follows that a topical
microbicide that compromises this normally potent cer-
vicovaginal barrier could substantially increase suscept-
ibility to HIV or other pathogens.
Traditional safety assessments of topical agents have
relied on gross, microscopic, or colposcopic examinations
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any medium, provided the original work is properly cited.of exposed tissue in animal and clinical studies to detect
and quantify tissue damage and inflammation. Recently,
more sensitive assessments of microbicide-induced inflam-
mation have been described employing measurement of
soluble cytokines [8], and by immunohistochemical stain-
ing of tissue inflammatory markers [9]. The slug mucosal
irritation assay has been developed as a rapid and quanti-
tative screening test to assess the irritative potential of
agents applied to mucosal surfaces [10,11], and to assess
diverse topical products and their ingredients. While valu-
able, both the traditional and these more recent methods
assess surrogate markers rather than directly testing for
toxicities that increase susceptibility to pathogen transmis-
sion, arguably the most dangerous of potential microbicide
toxicities.
We developed a mouse model that directly determines
whether microbicides cause, by any mechanism, toxicity
that increases the susceptibility of the vagina to the viral
STI pathogen HSV-2 [12]. We found that a single expo-
sures to the candidate microbicides nonoxynol-9 and
C31G caused a marked increase in susceptibility to
HSV-2, concordant with the increased susceptibility to
HIV with nonoxynol-9 observed in a Phase III clinical
microbicide trial [2], and a trend toward increased
transmission in a Phase III trial of C31G [3]. A similar
model has been reported, extending the evaluation to
include repeated test agent exposures, and likewise
demonstrated increased susceptibility to HSV-2 after
multiple nonoxynol-9 exposures [13]. Exposure to cellu-
lose sulfate was recently reported to increase susceptibil-
ity to HSV-2 in this multiple-exposure model [14],
concordant with the results of the per protocol analysis
of Phase III trial where cellulose sulfate was associated
with a significantly increased transmission of HIV [4].
These results support the utility of these mouse HSV-2
susceptibility models for predicting microbicide-induced
toxicities that increase HIV susceptibility in women.
Certain active pharmaceutical ingredients (APIs) such
as nonoxynol-9 have been shown to damage the epithe-
lial barrier in traditional animal and clinical studies [15],
and nearly all safety testing has focused exclusively on
detecting toxicities of microbicide APIs. Indeed, a com-
monly used study design has been to compare the active
product to a vehicle control (an identical formulation
minus the API), based on the belief that excipients are
nontoxic. However, this standard ‘vehicle control’ study
design inherently precludes detecting toxic effects of the
vehicle that might increase susceptibility to infection.
Although excipients are often called “inactive ingredi-
ents” and are widely considered to be benign, these ingre-
dients do have activities and toxicities, and none of the
excipients employed in microbicide development and
widely used in sexual lubricants or other vaginal products
have been tested in a manner that would disclose
whether or not they alter barrier functions or otherwise
increase HIV/STI susceptibility at mucosal surfaces.
Methods
Excipients and other materials
Propylparaben, methylparaben, sorbic acid, benzyl alco-
hol, EDTA disodium dihydrate, glycerin, propylene gly-
col, and PEG-8 (polyethylene glycol, monomer number
= 8, formula weight = 400 Daltons) were U.S.P. or N.F.
grades from Spectrum Chemicals & Laboratory Pro-
ducts, Gardena, CA. Hydroxyethylcellulose (HEC,
NATROSOL®, 250HX PHARM), was from Hercules
Incorporated, Wilmington, DE. Bartels® Tissue Culture
Refeeding Medium was from Trinity Biotech, St. Louis,
MO. Sodium chloride was from Fisher Scientific, Fair
Lawn, NJ. Phosphate buffered saline (PBS, Dulbecco’s
phosphate buffered saline) was from Sigma Aldrich,
St. Louis, MO. K-Y® Warming Jelly/Gelle was from
Johnson & Johnson Consumer Companies Inc, Skillman
NJ. Glycerol monolaurate (GML, Monomuls 90-L 12)
was from Cognis Corporation, Cincinnati, OH. Medrox-
yprogesterone acetate injectable suspension, USP was
from Sicor Pharmaceuticals, Inc. Irvine, CA.
Virus
HSV-2 Strain G (ATCC #VR-734, 2.8 × 10
7 TCID50 per
mL, was from American Type Culture Collection,
Manassas, VA), and was aliquoted and stored at- 85°C
until thawed for use. When thawed aliquots of this
stock were diluted 100-fold with Bartels medium, a
10 μL vaginal dose infected ~50% of the control animals
(1 intravaginal infectious dose50,o rI D 50).
Cell lines
Human foreskin fibroblasts in 96-well plates were from
Diagnostic Hybrids Inc. Athens, OH.
Animals
Female Hsd:NSA ™(CF-1®) out bred mice were 6-8
weeks old when obtained from Harlan Laboratories,
Indianapolis, IN, and were 7-12 weeks old at the time of
the studies. These mice were easily handled and no
anesthesia was used to deliver the test agents vaginally.
Preparation of formulations
The HEC “universal” placebo gel formulation (HEC pla-
cebo) [16,17], currently being used extensively in micro-
bicide trials [18], was used as a vehicle to which
compatible excipients were added for tests in the sus-
ceptibility model. The HEC placebo gel formulation
contains 2.7% HEC as the gel-forming polymer, 0.85%
sodium chloride for tonicity adjustment, 0.1% sorbic
acid as a preservative, and sodium hydroxide q.s. to
pH 4.4. All percentages were % w/w.
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of alternative preservatives. GML was formulated as a
5% (w/w) solution in K-Y Warming Jelly (KYWJ), as
described in publications assessing GML as a vaginal
microbicide [19,20]. To study GML (an agent with lim-
ited aqueous solubility in water) in a formulation lacking
the extreme hyperosmolality of KYWJ, a colloidal sus-
pension of 5% (w/v) GML in PBS was prepared by stir-
ring GML in PBS with a magnetic stirrer at 50°C for
one hour, and maintaining it at 37°C until vaginal
administration within 3 hours of preparation, with resti-
rring immediately before administration. Microscopic
examination showed this preparation to be a colloidal
suspension of ~25 micron diameter GML spherical glo-
bules, which remained stable in size for at least 6 hours
at 37°C. Concentrations of other excipients were chosen
to span substantial portions of the range of concentra-
tions used in vaginal or other topical formulations [21].
The humectant/solvents of KYWJ were tested neat to
determine their individual effects at extremely high
osmolalities similar to that of the parent KYWJ
formulation.
Osmolality measurements
Osmolality was measured with a vapor pressure osm-
ometer (VAPRO™ Model 5220 Wescor Inc., Logan, UT).
For agents or formulations with osmolality above the
range of the instrument (GML in KYWJ, KYWJ, PEG-8,
and propylene glycol), the osmolality was estimated by
linear extrapolation of a 1:3 (v/v) dilution of the product
with distilled water.
Dose-response relationship
To obtain the dose-response relationship, thawed ali-
quots of HSV-2 stock were diluted sequentially to deter-
mine the fraction of mice infected as a function of viral
intravaginal dose to cover the range from 0.1 ID50 to
10 ID50.
HSV-2 susceptibility model
The procedures were as previously described in detail
[12]. Briefly, female 7-12 week old CF-1 mice were
injected subcutaneously with 2.5 mg of medroxyproges-
terone acetate, and one week later received 20 μL of test
agent or PBS control intravaginally with a fire-polished
positive displacement capillary pipette (Wiretrol®, Drum-
mond Scientific, Broomall, PA). Twelve hours later,
mice were challenged with a 10 μL inoculum containing
1o r0 . 1I D 50 of HSV-2 in Bartels medium as specified
below. Mice were assessed for infection three days after
inoculation by culturing a PBS vaginal lavage on human
foreskin fibroblasts. Prior studies have demonstrated
that viral isolation gives very similar but slightly more
sensitive detection of infection than assessing HSV-2
disease (visible lesions) [22].
Statistical analysis
Data were analyzed by two-sided Fisher’se x a c tt e s t
comparing the number of animals infected after expo-
sure to the test agent vs. the number of control animals
infected after exposure to PBS using equal size groups
of test and control animals. For agents that showed a
significant increase in susceptibility, the increase in sus-
ceptibility was calculated as the effective infectious dose
read from the dose response curve (Figure 1) divided by
the infectious dose of the same inoculum in the control
animals. Sample size calculations were by standard
methods, with an incorporated continuity correction
[23], using proportions calculated from the dose-
response curve.
Results
Dose response relationship
The dose-response relationship between viral dose and
infectivity in progestin treated mice is shown in Figure 1.
A 100-fold dilution of the viral stock yielded 1 ID50 in
the 10 μL inoculum volume. When displayed on a semi-
log plot, the results show a sigmoid dose-response
relationship with a linear portion centered around one
Figure 1 The filled circles are the averages for groups of 60
mice for each viral dose. The curve is the best fit of the Michaelis-
Menten relationship, f = 1/(1 + dose
-1), for the dose response data.
The black square shows that 50% of animals treated with GML in
KYWJ became infected with a viral dose of 0.1 ID50, and the dashed
arrow indicates that this treatment caused a 10-fold increase in
susceptibility (see Table 2).
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the control animals (Figure 1). The results are well fit
with the Michaelis-Menton equation: fraction infected =
1/(1 + (dose)
-1) where dose is the viral dose expressed in
units of ID50. This dose-response curve was similar to
previous dose response curves obtained with other viral
stocks, including the controls in our previous study with
this model, which included a total of 550 mice [12] and
lay along a nearly identical curve defined by the Michae-
lis-Menton equation (data not shown).
The close agreement with the Michaelis-Menton
equation was consistent with “single-hit kinetics”, i.e.,
infections being initiated by single virions. In addition,
this close agreement suggests there was low variability
between mice and low variability in the inoculum
procedures since both these potential sources of varia-
bility would decrease the slope of the dose-response
relationship.
Sample size calculations
Statistical power calculations based on the dose-
response relationship in Figure 1 indicated that with a
v i r a ld o s eo f1I D 50 in the control animals, 500, 210,
and 100 animals divided equally between test and con-
trol animals are required to provide 80% power with
alpha = 0.05, to detect an increase in susceptibility of
2-fold, 3-fold and 5-fold, respectively.
Osmolality of test agents
The osmolality values reported in Table 1 are the means
of three determinations. The average coefficient of varia-
tion of replicate determinations was 2.5%. The agents
studied in the HEC placebo gel were only slightly hyper-
osmotic (~350 mOsm/kg compared with ~290 mOsm/
kg for blood and most body fluids), with the exception
of the formulations containing the humectant/solvent
agents, glycerin and propylene glycol, which were for-
mulated at 10% concentration and were moderately
hyperosmotic (~1700 mOsm/kg). In contrast, 30% gly-
cerin, KYWJ alone and KYWJ with 5% GML were extre-
mely hyperosmotic, as were the undiluted main
ingredients of KYWJ, propylene glycol and PEG-8.
Alterations in susceptibility to HSV-2 challenge
Table 1 shows the results of the susceptibility tests. The
parabens and benzyl alcohol preservatives showed no
increase in susceptibility. Animals treated with disodium
EDTA at 0.1% showed a trend toward increased suscept-
ibility that did not reach statistical significance (P = 0.095),
and those treated with 0.0186% disodium EDTA showed
no increase. A relatively low concentration (10%) of the
humectant/solvent compound propylene glycol did not
show an increase in susceptibility, but another humectant/
solvent at the same concentration, 10% glycerin, showed a
trend toward increased susceptibility, though it did not
reach statistical significance.
In contrast, the last six agents shown in Table 1 all
caused large and statistically significant increases in sus-
ceptibility. Five percent (5%) GML in KYWJ, and 5%
GML in a colloidal suspension in PBS significantly
increased susceptibility. The KYWJ vehicle and both its
component humectants/solvents, propylene glycol (neat)
and PEG-8 (neat), also caused large and highly signifi-
cant increases in susceptibility. An intermediate concen-
tration of another humectant/solvent, 30% glycerin in
HEC also caused a significant increase in susceptibility.
Since 5% GML in KYWJ, and KYWJ alone both
caused nearly all of the treated animals (more than 90%)
to become infected, additional tests were performed
with a lower-dose inoculum (0.1 ID50) to obtain a more
accurate measure of the magnitudes of the susceptibility
increases. This is the procedure used in our earlier stu-
dies of detergents and surface-active agents that also
caused large increases in susceptibility [12]. The results
are shown in Table 2. The treated animals were chal-
lenged with a ten-fold lower dose of virus than the con-
trol animals, 0.1 ID50 vs. 1 ID50, yet close to 50% of
animals were infected in all three groups. Thus, the test
agents increased susceptibility about 10-fold as indicated
by the black square and the dashed arrow in Figure 1.
Discussion
Excipients are often not inactive
Excipients are thought of as “inactive ingredients” but
often without evidence that they are inactive. Although
excipients can serve important functions ancillary to
active pharmaceutical ingredients (APIs) in topical
microbicide products, they bear their own potential toxi-
cities. We studied a broad range of excipient classes,
namely, preservative, antioxidant, chelating, humectant,
solublizing, and emulsifying excipients commonly used
in vaginal [21] and other topical products in an assay
that determines their impact on susceptibility to infec-
tion with HSV-2. We tested excipients in vehicles (i.e.,
HEC placebo gel; PBS solution) known to be free of
toxicities that increased susceptibility [12], and also
undiluted (neat) excipients, thus in isolation from any
API, thereby preventing antiviral activity by the API
from masking excipient-induced increases in susceptibil-
ity. Although it could be argued that an effective API
would make excipient-induced increases in susceptibility
irrelevant, in practice imperfect microbicide adherence,
the unpredictable timing of intercourse, and the pro-
longed duration of altered susceptibility [12] are such
that it cannot be assumed that effective levels of an API
will be present throughout the period of increased
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against all pathogens to which it or its excipients
increase susceptibility.
Preservatives might be expected to be of particular
concern since these agents kill or inhibit a broad range
of microorganisms and may also have similar cellular
toxicity. However, neither parabens nor benzyl alcohol
caused a detectable increase in susceptibility in our
model, despite an apparent association of benzyl alcohol
with irritative symptoms in a Phase I study of cellulose
sulfate [24]. Sorbic acid had previously been tested in
our initial studies with this model [12] without detect-
able increase in susceptibility. In the present studies, we
used the sorbic acid-preserved HEC placebo gel [16,17]
as a vehicle for tests of other excipients, and thereby
again confirmed the lack of increased susceptibility with
sorbic acid and the HEC placebo gel vehicle when com-
pared repeatedly to a PBS control. These findings also
match the benign clinical safety profile and lack of effect
on HIV transmission of the HEC placebo in an HIV effi-
cacy trial, where it was directly compared to a no-gel
arm [18].
EDTA is a chelating agent used as a preservative
synergist at 0.01-0.1% and as an antioxidant synergist at
0.005 to 0.1% [21,25]. We studied disodium EDTA at
two concentrations, 0.0186% and 0.1%. At 0.0186%
(~ 0.5 mM) disodium EDTA showed no effect on sus-
ceptibility to HSV-2. However, at the higher end of the
typically used concentrationr a n g e( 0 . 1 % ) ,t h e r ew a sa
trend toward increased susceptibility to HSV-2 challenge
(P = 0.095). Since EDTA has long been used to detach
mucosal epithelia in vitro [26], the trend toward harm at
the upper end of the typically used EDTA concentra-
tions, though not statistically significant, raises concern
about the safety of disodium EDTA at or beyond 0.1%.
Low molecular weight highly soluble organic com-
pounds are commonly used as “humectants” in derma-
tological formulations and sexual lubricants to reduce
evaporation-induced coldness and premature drying
when aqueous formulations are spread over the skin, as
well as for their lubricant character. The commonly
used humectants glycerin, propylene glycol, and PEG-8
are also employed for their solvent and/or preservative-
enhancing characters [25]. The slug mucosal irritation
assay reported toxicity (irritation and damage) with high
osmolality preparations, including Astroglide® (contain-
ing glycerin and propylene glycol, osmolality ~5800
mOsm/kg), and an HEC gel with glycerin added at both
20 and 40% and an osmolality of 2200-4400 mOsm/kg)
[11]. Several clinical studies likewise reported that other
Table 2 Animals challenged (0.1 or 1.0 ID50) and infected after pre-treatment with test agent or PBS
Agent administered 12 h before viral challenge Challenge dose 0.1 ID50 Challenge dose 1.0 ID50 Fold-increase susceptibility
GML in K-Y Warming Jelly 21/40 (53%) * 10
K-Y Warming Jelly 18/39 (46%) * 7
PBS * 21/40 (53%) Reference
*The exposures at challenge doses in these cells were not performed concurrently with the experiment reported in this Table, but results from previously
performed experiments at these doses are shown in Table 1 and Fig. 1.
Table 1 Summary of Susceptibility Studies: Mice challenged with 1 ID50 after pre-treatment with test agent or control
Test Agent administered 12 h
before viral challenge
Fraction infected after
Test Agent
Fraction infected after
PBS Control
P value Fold-increase in
susceptibility
Osmolality
(mOsm/kg)
Methylparaben/propylparaben
(0.18%/0.02%) in HEC gel
19/60 (32%) 20/60 (33%) 1 374
Benzyl alcohol (1%) in HEC gel 26/60 (43%) 26/60 (43%) 1 338
Disodium EDTA (0.1%) in HEC gel 59/90 (66%) 52/90 (58%) 0.095 2* 376
Disodium EDTA (0.0186%) in HEC gel 10/60 (17%) 14/60 (23%) 0.49 341
Propylene glycol (10%) in HEC gel 38/60 (63%) 33/60 (55%) 0.46 1,770
Glycerin (10%) in HEC gel 15/60 (25%) 23/60 (38%) 0.17 2* 1,700
Glycerin (30%) in HEC gel 32/59 (54%) 20/59 (34%) 0.04 3 4,280
GML (5%) in K-Y Warming Jelly 59/60 (98%) 28/60 (47%)♦ < 0.0001 > 10 10,100
K-Y Warming Jelly (neat) 57/60 (95%) < 0.0001 > 9 10,300
GML (5%) colloidal suspension in PBS 48/60 (80%) 33/60 (55%) 0.006 5 329
Propylene glycol (neat) 55/60 (92%) 28/59 (47%)♦ < 0.0001 10 9,990
Polyethylene glycol (PEG-8) (neat) 55/60 (92%) < 0.0001 10 5,610
♦ Control for both agents in the adjacent column in a three-arm experiment.
* Fold-increases were calculated for these formulations because of their strong, though not statistically significant, trends toward increased susceptibility.
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nar epithelium of the rectum [27-29]. In our studies, the
moderately hyperosmotic formulations of 10% glycerin
and 10% propylene glycol did not show a significant
increase in susceptibility, though 10% glycerin showed a
trend toward, and 30% glycerin caused a significant
increase in susceptibility. Moreover, consistent with the
reports of toxicity with the extremely hyperosmotic for-
mulations cited, we found that an extremely hyperosmo-
tic vehicle, KYWJ (osmolality > 10,000 mOsm/kg)
caused a 7-fold increase in susceptibility to HSV-2
(Table 2). Moreover, each of the primary constituents of
this formulation, the humectant/solvents propylene gly-
col and PEG-8, greatly increased susceptibility. Both are
markedly hyperosmotic, in the range of the complete
KYWJ formulation, and their osmolality may mediate
the toxicity. However, both are not only humectants,
but also solvents, and their toxicity may additionally or
alternatively be due to solvent properties or other char-
acteristics. Indeed, propylene glycol has been demon-
strated to have in vitro cellular toxicity at relatively low
concentrations, independent of osmotic effects [30].
GML and the hyperosmotic K-Y Warming Gel vehicle
Since our previous work with this model demonstrated
very large increases in susceptibility after exposure to a
diverse range of surfactants [12], and to the non-surfactant
but membrane-active chlorhexidine [12], we tested the
excipient glycerol monolaurate (GML). GML has surfac-
tant, emulsifier, membrane-active, and penetration-enhan-
cing actions. Moreover, GML is currently being studied as
a novel microbicide API [19], hypothesized to act by
down-regulating the activation, recruitment, and accumu-
lation of HIV target cells [19]. GML is poorly soluble in
water, and GML was formulated in the cited and present
studies using the non-aqueous lubricant KYWJ as a vehi-
cle, composed primarily of the low molecular weight
humectant/solvents propylene glycol and PEG-8.
Using an inoculum of 1 ID50,w ef o u n dt h a t5 %G M L
formulated in KYWJ, caused a 10-fold increase in sus-
ceptibility to HSV-2, somewhat greater than the increase
also observed after KYWJ vehicle alone. The rate of
infection with 1 ID50 approached 100%, limiting an
accurate estimation of the magnitude of susceptibility
increase. Therefore we did additional experiments with
a lower inoculum (0.1 ID50) and the results indicated
the susceptibility increased 10-fold with GML in KYWJ
and 7-fold with KYWJ alone. In light of the toxicity
associated with KYWJ, we tested 5% GML without this
vehicle, prepared as a colloidal suspension in PBS.
Although GML formulated in PBS was nearly isotonic,
it too significantly increased susceptibility (P < 0.006),
indicating that both KYWJ and GML individually caused
susceptibility-increasing toxicity.
The susceptibility-increasing toxicity of GML may be
due to its surface-active and membrane-active proper-
ties. Indeed its effects on toxin production and signaling
in bacteria and immune cells have been postulated to be
due to intercalation of GML into cell membranes
[31,32]. In light of the increase in susceptibility caused
by a wide diversity of surfactant types in our prior study
[12], and the surfactant nonoxynol-9 in a similar model
[13], the increased susceptibility observed after exposure
to GML is perhaps not unexpected. Yet it is notable
that neither colposcopic nor histological abnormalities
were detected after 6 months of daily vaginal adminis-
tration of 5% GML in KYWJ in rhesus macaques [20].
However, in our prior studies of the surfactant nonoxy-
nol-9, colposcopy was normal at the time of maximally
increased susceptibility to HSV-2, twelve hours after
exposure [12]. Moreover, our studies evaluated surfac-
tant contact with columnar-like epithelium of the
medroxyprogesterone acetate-treated mouse vagina
since microbicides will contact human columnar epithe-
lium in the endocervix [33]. Exposure to columnar
epithelium will also occur on the face of the cervix
when cervical ectopy is present. Examination of colum-
nar epithelium (endocervix or ectopy) was not reported
after chronic GML exposure in the GML toxicity study
in macaques [20].
The present findings are examples of unexpected
actions of excipients, and show that excipients are not
necessarily inactive, nor non-toxic in mucosal contact.
The previous demonstration of the effect of GML on
signaling and toxin production in bacteria [32], its effect
on cell immune cell proliferation [31], its activity as a
penetration enhancer, the recent demonstration of its
activity in inhibiting SIV [19], and the present demon-
stration of its action increasing susceptibility to genital
herpes are examples of substantial activities of an excipi-
ent. Likewise the HSV-2 susceptibility-increasing effects
of KYWJ, and the prior toxicity documented with
another hypertonic lubricant, ID Glide® [27], also illus-
trate the potential toxicity of vehicles (lubricant gels)
even in the absence of an API.
We tested an intermediate concentration (30%) of the
humectant/solvent glycerin because glycerin was toxic in
this concentration range in an in vitro model [11], and
is present in the gel formulation used in CAPRISA 004,
where 1% tenofovir vaginal gel was reported to provide
protection against both HIV and HSV-2. Thirty percent
glycerin caused a significant increase in HSV-2 suscept-
ibility in our model.
Choice of challenge dose and estimation of fold-increase
in susceptibility
In our previous publication [12] the surfactants tested
caused very large increases in susceptibility, and we
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accurate evaluation of the magnitudes of increased sus-
ceptibility. With agents of unknown, and perhaps only
modest effects on susceptibility, an inoculum size of 1
ID50 is optimal for providing maximum statistical power
to detect significant alterations in susceptibility. It is
n o t a b l et h a tal a r g en u m b e ro fa n i m a l sw a sr e q u i r e dt o
detect even fairly substantial increases in HSV-2 sus-
ceptibility (see Sample size calculations in Results). It is
also worth emphasizing, as illustrated in Figure 1, it is
inappropriate to calculate the magnitude of the increase
in susceptibility simply by stating the ratio of the frac-
tions of animals infected in the test and control groups.
For example, with a challenge dose of 1 ID50, even an
agent that increases susceptibility by 1000-fold could
only double the fraction of animals infected. In contrast,
human transmission of HSV-2 infections typically
occurs with low probability of infection per coital event,
implying ‘low-dose’ viral challenges. In such cases,
increased susceptibility as defined here implies the prob-
ability of transmission per coital event will likely
increase by the magnitude that the agent increases sus-
ceptibility; a 10-fold increase in susceptibility would lead
to a 10-fold increase in human transmission rate.
Limitations and strengths of this model
Our model has several limitations. Observations were
made in mice rather than humans or non-human pri-
mates. Medroxyprogesterone acetate-treated mice have a
thinned epithelium with living cells on the surface,
mimicking columnar epithelium and probably with
greater sensitivity to chemical damage or irritation than
the multilayer squamous epithelium of the human vagi-
nal epithelium. However, vaginal microbicides contact
the columnar epithelium in the endocervix [33] via the
well-documented mechanism of uterine peristaltic
uptake [34-36] and also contact columnar epithelium on
the ectocervix when cervical ectopy is present. It is
appropriate for a screening test to be highly sensitive,
and to mimic the exposures that are potentially most
damaging. Moreover, vaginal microbicides will very
likely be used to attempt rectal protection, where they
will also contact columnar epithelium. For both these
reasons, a model exposing a thin epithelium with living
surface cells is highly relevant.
The challenge virus in this model is HSV-2, whereas
HIV is the primary focus of most microbicide develop-
ment efforts. However, it is plausible that toxicities that
result in heightened susceptibility to HSV-2 may also
increase susceptibility to HIV. Indeed results from our
model with nonoxynol-9 and C31G, and a similar model
[13] with nonoxynol-9, and cellulose sulfate, have corre-
lated well with significantly harmful (nonoxynol-9, cellu-
lose sulfate) or borderline harmful (C31G) clinical trial
results. Moreover, HSV-2 is an important pathogen in
its own right, and as a cofactor that substantially
increases the risk of HIV acquisition. We therefore
believe that a microbicide whose API, component exci-
pients, or complete formulation significantly increase
susceptibility to HSV-2 in mice cautions against advan-
cing to clinical trials in humans.
In the present study, we investigated only a single
time interval between application of the test agent and
viral challenge. We elected to use the interval found to
be associated with the maximum increase in sensitivity
after exposure to the surfactant nonoxynol-9. However,
we acknowledge that the timing of maximum suscept-
ibility may vary depending on the agent tested.
Our model employs only a single exposure rather than
repeated exposures over time. We chose this exposure
protocol because in pilot experiments, multiple expo-
sures with the surfactant microbicide nonoxynol-9 did
not result in greater susceptibility than a single exposure
(data not shown). In addition, the single-exposure model
allows resources to be directed toward increasing the
number of animals in groups, possibly providing greater
overall sensitivity of the model. However, some agents
may only show toxicities after multiple exposures, for
example agents that are sensitizers, where inflammatory/
immune-mediated toxicities may only be observed after
sub-chronic or chronic dosing schedules.
Finally, neither this nor any model can be certain to
detect all possible toxicities, and hence lack of toxicity
in this model does not guarantee safety in human use.
Conversely, when this or similar models detect increases
in susceptibility to important STI pathogens, we believe
such results should be considered important red flags
cautioning against the use of an API, excipient, or com-
pleted formulation in the vagina or rectum.
Our model has the following strengths: It directly
detects toxicities that result in heightened susceptibility
to HSV-2 acquisition, rather than surrogate endpoints
that are only postulated to cause increased susceptibility.
It thus directly assesses what may be reasonably consid-
ered one of the most harmful potential toxicities of a
candidate microbicide, a paradoxical increase in suscept-
ibility to a serious sexually transmitted viral pathogen.
Importantly, the results in this and similar models [13]
correlate well with trends toward or statistically signifi-
cant adverse effects of microbicides on HIV endpoints
in clinical studies [1-4]. The model is efficient and sensi-
tive, employing genital tract tissue with highly suscepti-
ble living surface cells and an optimized inoculum
strength. It can use sufficient animals to provide statisti-
cal power to detect relatively small changes in suscept-
ibility, increases in susceptibility increases as low as 3-5
fold over controls. We believe it can provide useful
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Page 7 of 9guidance on the suitability of APIs and excipients for
use in vaginal microbicide formulations.
Conclusions
Increased susceptibility caused by a candidate microbi-
cide or excipient in this and similar animal models cau-
tions against its advancement to clinical trials. Our
results specifically caution against the use of KYWJ as a
vehicle, glycerin at or above 30%, or high concentrations
of PEG-8 or propylene glycol as excipients, and GML as
an excipient or API. Although not significant, the trends
toward harm with 0.1% disodium EDTA and 10% gly-
cerin also argues for caution at or above these concen-
trations in microbicide or other vaginal formulations.
Conversely, our results are reassuring regarding the suit-
ability of the lower dose disodium EDTA and the other
preservatives and humectants at the concentrations
tested.
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